Zynerba Pharmaceuticals (Nasdaq:ZYNE) - Cotización, noticias y análisis

Resumen de acción ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.

ZYNE fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 97.6% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 67.21%

Los beneficios han crecido un 0.8% al año en los últimos 5 años

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Tiene menos de 1 año de cash runway

Alta volatilidad del precio de la acción en los últimos 3 meses

No tiene una capitalización de mercado significativa ($66M)

+ 2 riesgos adicionales

Competidores de Zynerba Pharmaceuticals, Inc.

Ikena Oncology

NasdaqGM:IKNA

US$62.7m

Landos Biopharma

NasdaqCM:LABP

US$69.7m

Anebulo Pharmaceuticals

NasdaqCM:ANEB

US$70.1m

Cognition Therapeutics

NasdaqGM:CGTX

US$76.1m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Zynerba Pharmaceuticals
Historical stock prices
Current Share Price	US$1.30
52 Week High	US$1.40
52 Week Low	US$0.25
Beta	1.19
1 Month Change	-1.52%
3 Month Change	282.24%
1 Year Change	96.08%
3 Year Change	-65.79%
5 Year Change	-82.17%
Change since IPO	-92.00%

Noticias y actualizaciones recientes

Recent updates

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Mar 01

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 11

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Oct 06

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Aug 10

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Jul 22

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Jul 21

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Mar 23

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Dec 02

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

May 27

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Dec 17

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 23

Zynerba Pharmaceuticals EPS beats by $0.12

Nov 09

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

Oct 29

Rentabilidad de los accionistas

	ZYNE	US Pharmaceuticals	Mercado US
7D	4.0%	0.7%	2.9%
1Y	96.1%	10.8%	22.2%

Rentabilidad vs. Industria: ZYNE superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 10.6% el año pasado.

Rentabilidad vs. Mercado: ZYNE superó al mercado US, que obtuvo un rendimiento del 21.9% el año pasado.

Volatilidad de los precios

Is ZYNE's price volatile compared to industry and market?
ZYNE volatility
ZYNE Average Weekly Movement	84.2%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de ZYNE ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ZYNE ha aumentado de 43% a 84% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2007	26	Armando Anido	www.zynerba.com

Resumen de fundamentos de Zynerba Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de Zynerba Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de ZYNE
Capitalización bursátil	US$65.60m
Beneficios(TTM)	-US$37.58m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-1.7x

Ratio precio-beneficio (PE)

¿Está ZYNE sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ZYNE
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$37.58m
Beneficios	-US$37.58m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.74
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado ZYNE a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ZYNE

Recompensas

Análisis de riesgos

Competidores de Zynerba Pharmaceuticals, Inc.

NasdaqGM:IKNA

US$62.7m

NasdaqCM:LABP

US$69.7m

NasdaqCM:ANEB

US$70.1m

NasdaqGM:CGTX

US$76.1m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

Price target decreased by 78% to US$1.26

New minor risk - Profitability

Recent updates

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

Price target decreased by 78% to US$1.26

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Price target increased by 7.9% to US$5.80

Forecast to breakeven in 2025

Price target increased by 30% to US$7.00

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$5.44

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Price target increased to US$8.33

Insufficient new directors

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Price target decreased to US$6.95

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Price target decreased to US$6.95

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

New 90-day high: US$5.08

New 90-day low: US$3.27

Zynerba Pharmaceuticals, Inc. Provides Regulatory Update on Zygel™ in Fragile X Syndrome

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

New 90-day high: US$3.88

Zynerba Pharmaceuticals EPS beats by $0.12

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

New 90-day low: US$3.23